利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.015 秒)

    IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME
    2.
    发明申请
    IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME 审中-公开
    免疫细胞组合物及其使用方法

    公开(公告)号：WO2017100428A1

    公开(公告)日：2017-06-15

    申请号：PCT/US2016/065578

    申请日：2016-12-08

    申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

    发明人： ADUSUMILLI, Prasad, S.

    IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0781

    CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/03 ,  C12N5/0637 ,  C12N2501/505 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2510/00

    摘要： Disclosed herein are cells that are immunoinhibitory cell, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the cell. In certain embodiments, the immunoinhibitory cell is a regulatory T cell. In another aspect, provided herein is a regulatory T cell that recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response. The cells can be sensitized to an antigen that is the target of a pathologic immune response associated with an immune-mediated disorder. Additionally provided are methods of using such cells to treat an immune-mediated disorder in a subject in need thereof.

    摘要翻译： 本文公开了作为免疫抑制性细胞的细胞，所述细胞重组表达细胞介导的细胞免疫应答抑制剂的显性失活形式。 在某些实施方案中，免疫抑制性细胞是调节性T细胞。 另一方面，本文提供了调节性T细胞，其重组表达调节性T细胞介导的免疫应答抑制剂的显性失活形式。 细胞可以对作为与免疫介导的病症相关的病理性免疫应答的靶标的抗原敏化。 另外提供了在有此需要的受试者中使用此类细胞治疗免疫介导的病症的方法。

    IMMUNE CELL COMPOSITIONS AND METHODS OF USE FOR TREATING VIRAL AND OTHER INFECTIONS
    3.
    发明申请
    IMMUNE CELL COMPOSITIONS AND METHODS OF USE FOR TREATING VIRAL AND OTHER INFECTIONS 审中-公开
    免疫细胞组合物和用于治疗病毒和其他感染的方法

    公开(公告)号：WO2018044866A1

    公开(公告)日：2018-03-08

    申请号：PCT/US2017/049085

    申请日：2017-08-29

    申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

    发明人： ADUSUMILLI, Prasad, S.

    IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28

    摘要： Disclosed herein are cells that are immune cells, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, and optionally recombinantly express a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen. In certain embodiments, the immune cell is an immunostimulatory cell, such as a T cell. In certain embodiments, the immune cell is an immunoinhibitory cell, such as a regulatory T cell. Also disclosed herein are immune cells that recognize and are sensitized to a viral antigen, which immune cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell. The cells can be sensitized to an antigen that is a viral antigen. Additionally provided are methods of using such cells to treat a viral infection in a subject in need thereof.

    摘要翻译： 本文公开了作为免疫细胞的细胞，所述细胞重组表达显性阴性形式的免疫细胞的细胞介导的免疫应答抑制剂，并任选地重组表达嵌合抗原受体（CAR ），其中CAR结合病毒抗原。 在某些实施方案中，免疫细胞是免疫刺激细胞，如T细胞。 在某些实施方案中，免疫细胞是免疫抑制性细胞，例如调节性T细胞。 本文还公开了识别病毒抗原并对其敏感的免疫细胞，所述免疫细胞重组表达显性失活形式的免疫细胞的细胞介导的免疫应答抑制剂。 细胞可以对作为病毒抗原的抗原敏化。 另外提供了使用此类细胞来治疗有需要的受试者的病毒感染的方法。

    CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF
    5.
    发明申请
    CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF 审中-公开

    公开(公告)号：WO2021113432A1

    公开(公告)日：2021-06-10

    申请号：PCT/US2020/062992

    申请日：2020-12-03

    申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER

    发明人： ADUSUMILLI, Prasad, S. ,  XIONG, Yuquan

    IPC分类号： C07K14/82 ,  C07K16/28 ,  A61K39/395 ,  C07K19/00 ,  A61P35/00

    摘要： The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to cells comprising a c-Kit mutant, e.g., a c-Kit mutant comprising an activating mutation. The cells can further comprise an antigen- recognizing receptor (e.g., a chimeric antigen receptors (CAR) or a T cell receptors (TCR)). The presently disclosed subject matter relates to the use of cells for treatment, e.g., treating cancers.